Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects
- 1 August 1988
- journal article
- research article
- Published by Wiley in Teratology
- Vol. 38 (2), 135-144
- https://doi.org/10.1002/tera.1420380206
Abstract
Medroxyprogesterone acetate (MPA; Provera) was given orally to 449 women from the 5th to 7th week of pregnancy until at least the 18th week. Data are recorded from two treatment groups (recurrent abortion and threatened abortion) and are compared to a matched series. A total of 1,016 pregnancies are included in the study, and all patients were recruited from a subfertile population conceiving from a range of infertility treatments. Early pregnancy wastage was high throughout the groups and was significantly elevated (43%; P <.001) in those women who had vaginal bleeding in early pregnancy. The study focuses on the question of potential teratogenicity of progestagens administered in the first trimester. There were 15/366 (4.1%) infants with congenital abnormalities in the MPA-treated group and 15/428 in the untreated group (3.5%). The difference was not significant, and MPA is considered to have no embryopathic risk, nor is it likely to retain an abnormal fetus that might otherwise abort. It appears that MPA is a safe drug to use in pregnancy although the question of efficacy has not been addressed in this report. Considering other recent negative epidemiologic studies with regard to teratogenicity, we add to the conclusion that MPA cannot be demonstrated to have a measurable teratogenic risk and certainly does not present a risk for congenital heart disease and limb reduction defects.This publication has 29 references indexed in Scilit:
- Developmental assessment of twenty in vitro fertilization (IVF) infants at their first birthdayJournal of Assisted Reproduction and Genetics, 1986
- Evaluation of Bendectin embryotoxicity in nonhuman primates: I. Ventricular septal defects in prenatal macaques and baboonTeratology, 1985
- Heterotopic pregnancy from in vitro fertilizationJournal of Assisted Reproduction and Genetics, 1985
- The World Collaborative Report on in Vitro Fertilization and Embryo Replacement: Current State of the Art in January 1984aAnnals of the New York Academy of Sciences, 1985
- Hormonal profiles in the follicular phase, luteal phase and first trimester of pregnancies arising from in‐vitro fertilizationBJOG: An International Journal of Obstetrics and Gynaecology, 1985
- Medroxyprogesterone acetate does not perturb the profile of steroid metabolites in urine during pregnancyJournal of Endocrinology, 1985
- Fetal abnormality (Goldenhar syndrome) occurring in one of triplet infants derived from in vitro fertilization with possible monzygotic twinningJournal of Assisted Reproduction and Genetics, 1985
- PREGNANCY RESULTS FOLLOWING TREATMENT WITH CLOMIPHENE CITRATEBJOG: An International Journal of Obstetrics and Gynaecology, 1971
- HORMONES IN RECURRENT ABORTIONBJOG: An International Journal of Obstetrics and Gynaecology, 1965
- The Progestational Activity of 6-Methyl-17-AcetoxyprogesteroneSouthern Medical Journal, 1959